Cardiac Fibrosis : The Fibroblast Awakens
© 2016 American Heart Association, Inc..
Myocardial fibrosis is a significant global health problem associated with nearly all forms of heart disease. Cardiac fibroblasts comprise an essential cell type in the heart that is responsible for the homeostasis of the extracellular matrix; however, upon injury, these cells transform to a myofibroblast phenotype and contribute to cardiac fibrosis. This remodeling involves pathological changes that include chamber dilation, cardiomyocyte hypertrophy and apoptosis, and ultimately leads to the progression to heart failure. Despite the critical importance of fibrosis in cardiovascular disease, our limited understanding of the cardiac fibroblast impedes the development of potential therapies that effectively target this cell type and its pathological contribution to disease progression. This review summarizes current knowledge regarding the origins and roles of fibroblasts, mediators and signaling pathways known to influence fibroblast function after myocardial injury, as well as novel therapeutic strategies under investigation to attenuate cardiac fibrosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
|---|---|
| Enthalten in: |
Circulation research - 118(2016), 6 vom: 18. März, Seite 1021-40 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Travers, Joshua G [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.07.2016 Date Revised 11.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCRESAHA.115.306565 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM258526483 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM258526483 | ||
| 003 | DE-627 | ||
| 005 | 20231224185209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCRESAHA.115.306565 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0861.xml |
| 035 | |a (DE-627)NLM258526483 | ||
| 035 | |a (NLM)26987915 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Travers, Joshua G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiac Fibrosis |b The Fibroblast Awakens |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2016 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2016 American Heart Association, Inc. | ||
| 520 | |a Myocardial fibrosis is a significant global health problem associated with nearly all forms of heart disease. Cardiac fibroblasts comprise an essential cell type in the heart that is responsible for the homeostasis of the extracellular matrix; however, upon injury, these cells transform to a myofibroblast phenotype and contribute to cardiac fibrosis. This remodeling involves pathological changes that include chamber dilation, cardiomyocyte hypertrophy and apoptosis, and ultimately leads to the progression to heart failure. Despite the critical importance of fibrosis in cardiovascular disease, our limited understanding of the cardiac fibroblast impedes the development of potential therapies that effectively target this cell type and its pathological contribution to disease progression. This review summarizes current knowledge regarding the origins and roles of fibroblasts, mediators and signaling pathways known to influence fibroblast function after myocardial injury, as well as novel therapeutic strategies under investigation to attenuate cardiac fibrosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a disease progression | |
| 650 | 4 | |a extracellular matrix | |
| 650 | 4 | |a fibroblasts | |
| 650 | 4 | |a fibrosis | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a therapeutics | |
| 650 | 7 | |a Inflammation Mediators |2 NLM | |
| 700 | 1 | |a Kamal, Fadia A |e verfasserin |4 aut | |
| 700 | 1 | |a Robbins, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Yutzey, Katherine E |e verfasserin |4 aut | |
| 700 | 1 | |a Blaxall, Burns C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation research |d 1953 |g 118(2016), 6 vom: 18. März, Seite 1021-40 |w (DE-627)NLM000001910 |x 1524-4571 |7 nnns |
| 773 | 1 | 8 | |g volume:118 |g year:2016 |g number:6 |g day:18 |g month:03 |g pages:1021-40 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCRESAHA.115.306565 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 118 |j 2016 |e 6 |b 18 |c 03 |h 1021-40 | ||